Elsewhere, Novavax is advancing new vaccines through the pipeline. It plans to start phase 3 studies for a combination coronavirus/flu vaccine and a stand-alone flu vaccine in the fourth quarter.

Sanofi is hopeful however that it can use Novavax' technology to create a combo ... Looking Ahead - Pipeline Assets May Reinforce Sanofi's Key Strengths - Solid Top Line Growth Promised Sanofi ...

Novavax's stock has been surging this year ... Until the company has a more promising product in its pipeline, which doesn't center around COVID or seasonal flu infections (where there is plenty ...

The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for influenza and COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the ...

With this outlook, the company expects to reveal an expanded clinical pipeline before the end of the year. Novavax reported revenue of $415.484 million, largely driven by the Sanofi collaboration.

The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is ...

Additionally, the analyst has increased the probability of success (PoS) for the aesthetics pipeline ... focusing on stocks such as Novavax, Agios Pharma, and Revolution Medicines.

Well-positioned with proven technology, pipeline assets, commercial execution, and a focus on corporate development, Novavax’s platform seems to stand it in good stead for its desired future.

Novavax is a biotechnology company that discovers ... three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Its pipeline products include NVX-CoV2373 for ...

The Novavax vaccine targets JN.1 ... Those losses could rise to $100 trillion by 2050 if the weak pipeline for new antibiotics continues to falter. Incorporating an 'AMR lens' into investment ...